Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTMXNASDAQ:PRPHNASDAQ:RENBNASDAQ:RPTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$0.66-7.5%$0.63$0.40▼$5.85$52.55M1.342.69 million shs1.52 million shsPRPHProPhase Labs$0.34-3.5%$0.38$0.22▼$5.62$14.11M-0.562.63 million shs287,829 shsRENBRenovaro$0.35-3.8%$0.62$0.32▼$2.34$55.55M0.59936,075 shs564,377 shsRPTXRepare Therapeutics$1.33-2.6%$1.12$0.89▼$4.29$56.33M0.91274,971 shs55,252 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics-0.30%-5.60%+12.69%-16.74%-55.48%PRPHProPhase Labs-5.04%+12.93%-20.39%-23.85%-92.56%RENBRenovaro-2.52%-9.43%-37.28%-56.45%-76.22%RPTXRepare Therapeutics+8.80%+13.33%+29.52%+18.26%-57.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTMXCytomX Therapeutics4.0109 of 5 stars3.31.00.04.72.12.51.3PRPHProPhase Labs1.0485 of 5 stars0.02.00.00.02.71.71.3RENBRenovaro1.3676 of 5 stars0.02.00.00.03.33.30.6RPTXRepare Therapeutics3.5789 of 5 stars3.35.00.00.03.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTMXCytomX Therapeutics 2.60Moderate Buy$4.77628.63% UpsidePRPHProPhase Labs 0.00N/AN/AN/ARENBRenovaro 0.00N/AN/AN/ARPTXRepare Therapeutics 2.50Moderate Buy$4.50239.62% UpsideCurrent Analyst Ratings BreakdownLatest PRPH, RPTX, RENB, and CTMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025CTMXCytomX TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$3.25 ➝ $2.503/7/2025CTMXCytomX TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.003/7/2025CTMXCytomX TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/7/2025RPTXRepare TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $5.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTMXCytomX Therapeutics$138.10M0.38N/AN/A($0.71) per share-0.92PRPHProPhase Labs$6.77M2.09N/AN/A$2.74 per share0.12RENBRenovaroN/AN/AN/AN/A$0.52 per shareN/ARPTXRepare Therapeutics$53.48M1.05N/AN/A$5.03 per share0.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTMXCytomX Therapeutics-$570K$0.383.86N/AN/A10.96%-41.47%8.11%5/6/2025 (Estimated)PRPHProPhase Labs-$16.78M-$1.26N/AN/AN/A-217.64%-62.92%-30.22%5/8/2025 (Estimated)RENBRenovaro-$80.65M-$0.93N/A∞N/AN/A-61.84%-48.07%5/13/2025 (Estimated)RPTXRepare Therapeutics-$93.80M-$2.00N/AN/AN/A-99.76%-40.87%-35.07%5/6/2025 (Estimated)Latest PRPH, RPTX, RENB, and CTMX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CTMXCytomX Therapeutics$0.10N/AN/AN/A$35.42 millionN/A5/8/2025Q1 2025PRPHProPhase Labs-$0.18N/AN/AN/A$2.45 millionN/A5/6/2025Q1 2025RPTXRepare Therapeutics-$0.65N/AN/AN/AN/AN/A3/6/2025Q4 2024CTMXCytomX Therapeutics-$0.23$0.22+$0.45$0.22$13.53 million$38.09 million3/3/2025Q4 2024RPTXRepare Therapeutics-$0.77-$0.67+$0.10-$0.67$0.67 millionN/A2/19/2025Q2 2025RENBRenovaroN/A-$0.02N/A-$0.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTMXCytomX TherapeuticsN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ARENBRenovaroN/AN/AN/AN/AN/ARPTXRepare TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTMXCytomX TherapeuticsN/A1.041.04PRPHProPhase Labs0.481.471.33RENBRenovaroN/A0.060.08RPTXRepare TherapeuticsN/A6.456.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTMXCytomX Therapeutics67.77%PRPHProPhase Labs9.45%RENBRenovaro71.41%RPTXRepare Therapeutics85.09%Insider OwnershipCompanyInsider OwnershipCTMXCytomX Therapeutics7.00%PRPHProPhase Labs20.70%RENBRenovaro21.72%RPTXRepare Therapeutics21.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTMXCytomX Therapeutics17080.10 million72.78 millionOptionablePRPHProPhase Labs13041.88 million18.93 millionOptionableRENBRenovaro20158.72 million124.24 millionOptionableRPTXRepare Therapeutics18042.51 million33.33 millionOptionablePRPH, RPTX, RENB, and CTMX HeadlinesRecent News About These CompaniesWhy Repare Therapeutics Inc.’s (RPTX) Stock Is Up 5.60%April 29 at 8:38 AM | aaii.comRepare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Down 20.4% in MarchApril 22, 2025 | marketbeat.comCathie Wood’s ARK ETF focuses on GitLab stock, sheds Repare TherapeuticsApril 15, 2025 | investing.comRepare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeedsApril 1, 2025 | markets.businessinsider.comLifeSci Capital Reaffirms Their Hold Rating on Repare Therapeutics (RPTX)April 1, 2025 | markets.businessinsider.comRepare Therapeutics Names Forte as President, CEOMarch 31, 2025 | marketwatch.comRepare Therapeutics Announces Leadership TransitionsMarch 31, 2025 | businesswire.comWhat Makes Repare Therapeutics (RPTX) a New Buy StockMarch 11, 2025 | zacks.comRepare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 7, 2025 | businesswire.comRepare Therapeutics price target lowered to $5 from $10 at H.C. WainwrightMarch 7, 2025 | markets.businessinsider.comHere's Why We're Watching Repare Therapeutics' (NASDAQ:RPTX) Cash Burn SituationMarch 4, 2025 | uk.finance.yahoo.comRepare Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 4, 2025 | finance.yahoo.comRepare Therapeutics Reduces Workforce by 75 PercentMarch 3, 2025 | precisionmedicineonline.comRepare Therapeutics reports Q4 EPS (67c), consensus (79c)March 3, 2025 | markets.businessinsider.comLifeSci Capital Sticks to Its Hold Rating for Repare Therapeutics (RPTX)March 3, 2025 | markets.businessinsider.comRepare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 3, 2025 | businesswire.comLifeSci Capital Remains a Hold on Repare Therapeutics (RPTX)February 26, 2025 | markets.businessinsider.comRepare Therapeutics to cut 75% of workforce in major restructuringFebruary 26, 2025 | thepharmaletter.comRepare Therapeutics to Cut Staff Again, This Time by 75%February 25, 2025 | biospace.comRepare unveils scale of layoffs with 75% of staff and chief medical officer heading for exitFebruary 25, 2025 | fiercebiotech.comCambridge-Montreal biotech lets go 75% of employeesFebruary 25, 2025 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRPH, RPTX, RENB, and CTMX Company DescriptionsCytomX Therapeutics NASDAQ:CTMX$0.66 -0.05 (-7.47%) As of 02:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.ProPhase Labs NASDAQ:PRPH$0.34 -0.01 (-3.51%) As of 02:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Renovaro NASDAQ:RENB$0.35 -0.01 (-3.79%) As of 02:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.Repare Therapeutics NASDAQ:RPTX$1.32 -0.04 (-2.57%) As of 02:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
